恒生创新药ETF（159316）盘中净申购超1.2亿份，国产创新药全球竞争力有望持续增强

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a strong performance, with the Hang Seng Innovative Drug Index rising by 1% as of 14:26, indicating positive market sentiment towards Chinese innovative pharmaceutical companies [1] Group 1: Market Performance - The Hang Seng Innovative Drug Index saw a rise of 1%, with notable gains from stocks such as Cloudtop New Drug rising over 5%, and Zai Lab and Four Rings Pharma both increasing over 3% [1] - The Hang Seng Innovative Drug ETF (159316) recorded a net subscription of over 120 million units during the trading session, reflecting strong investor interest [1] Group 2: Industry Developments - At the 2025 European Society for Medical Oncology (ESMO) annual meeting, Chinese innovative drug companies contributed over 440 abstracts, with 32 studies included in the latest breakthrough abstracts, showcasing their research capabilities across multiple cancer types [1] - According to Industrial Securities, the innovative drug sector's favorable conditions are expected to persist, with the "innovation + internationalization" trend remaining a core focus of the pharmaceutical industry [1] Group 3: Investment Opportunities - The innovative drug industry is anticipated to continue receiving policy support, enhancing the global competitiveness of Chinese innovative drugs and ensuring ongoing commercial profitability [1] - The Hang Seng Innovative Drug Index has been designed to exclude CXO, making it the first "pure" innovative drug index with 100% purity, accurately reflecting the overall performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index in the market, providing investors with a streamlined way to capitalize on opportunities in the innovative drug sector [1]